Source:http://linkedlifedata.com/resource/umls/id/C1312991
NCI: Monoclonal recombinant antibody J591 (mAb HuJ591) recognizes the extracellular domain of prostate specific membrane antigen (PSMA), a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells of numerous solid tumor malignancies. Early results of clinical Phase I and II studies indicate that mAb HuJ591 represents targeted therapy to PSMA and has therapeutic potential in disseminated prostate cancer and other urological and solid tumor malignancies and did not result in a host immune response to the antibody. (NCI)